A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma

A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma

Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) significantly improve the outcomes of patients with advanced clear cell renal cell carcinoma (ccRCC); however, high-grade toxicities can occur, particularly during combination therapy. Herein, we report a patient with advanced...

Full description

Bibliographic Details
Main Authors: Karim Gourari, Julien Catherine, Soizic Garaud, Joseph Kerger, Antonia Lepida, Aspasia Georgala, Fabienne Lebrun, Maria Gomez Galdon, Thierry Gil, Karen Willard-Gallo, Mireille Langouo Fontsa
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Diagnostics
Subjects:
checkpoint inhibitors
immune related adverse events
cholestasis
severe ductopenia
vanishing bile duct syndrome
Online Access:https://www.mdpi.com/2075-4418/12/2/539

Similar Items

Similar Items